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Abstract 
GPR39 is a class A G protein-coupled receptor involved in zinc binding and glucose 
homeostasis regulation, among other physiological processes. GPR39 was originally 
thought to be the receptor for obestatin peptide but this view has been challenged. 
However, activation of this receptor by zinc has been clearly established. Recent 
studies suggest that low GPR39 expression, due to deficient zinc levels, is involved in 
major depressive disorder. We have previously reported that zinc can alter receptor-
receptor interactions and favor specific receptor interactions. In order to unravel the 
effect of zinc on specific G protein-coupled receptor association processes, we have 
performed FRET and co-immunopurification studies with GPR39 and 5-HT1A and 
GalR1 which have been shown to dimerize. Our results suggest that zinc can modulate 
the formation of specific 5-HT1A-GPR39 and GalR1-5-HT1A-GPR39 heteroreceptor 
complexes under our experimental conditions. 
We have analyzed the differences in signaling between the mono-homomeric 
receptors 5-HT1A, GalR1 and GPR39 and the heteroreceptor complexes between them 
Our results show that the GPR39-5-HT1A heterocomplex has additive functionalities 
when compared to the monomeric-homomeric receptors upon receptor activation. In 
addition, the heterocomplex including also GalR1 shows a different behavior, upon 
exposure to the same agonists. Furthermore, these processes appear to be regulated by 
zinc. These findings provide a rationale for the antidepressive effect widely described 
for zinc because pro-depressive heterocomplexes are predominant at low zinc 
concentration levels.  
 
Keywords: depression, G protein-coupled receptor, heterooligomerization, purified 
receptor, signal transduction, zinc.  
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1 Introduction 
GPR39 is a member of the rhodopsin family of class A G protein-coupled receptors 
(GPCRs) [1]. It was first cloned in 1997 [2] and described as two isoforms; the full-
length receptor (GPR39-1a) and a truncated transmembrane domain isoform (termed 
GPR39-1b). Until now, however, its specific ligand is still a matter of debate. For 
instance, it was initially thought to be the receptor for the obestatin peptide [3], but no 
clear reproducible data have been reported to confirm this proposal [4, 5]. 
Furthermore, activation of the receptor by zinc, which would function as an agonist 
only for the full-length GPR39-1a isoform [6], has been also widely described [4, 5].  
A wide variety of physiological roles have been described for this receptor, like 
regulation of gastrointestinal and metabolic functions [7] and apoptosis protection [8], 
or its involvement in certain disorders like obesity type 2 associated diabetes mellitus 
[9], pancreatic islet dysfunction [10], cancer [11] and depression [12, 13]. In this work 
we have focused on the potential involvement of GPR39 in depression. There is 
consensus on the fact that GPR39 can be activated by zinc and there is growing 
evidence that this interaction may be involved in the pathophysiology of depression 
[12, 13]. One of the main current hypotheses is that a zinc deficient environment can 
result in decreased expression of GPR39 and this may be linked to depressive 
behavior. The association of GPR39, zinc and depression is appealing and may be 
parallel to our observed effect of zinc on 5-hydroxytriptamine 1A receptor (5-HT1A)-
galanin receptor 1 (GalR1) heteromer [14]. The current study was based on a previous 
hypothesis, which suggested that 5-HT1A-GalR1 heteromer is involved in major 
depressive disorder [15], and it was concluded that zinc may disrupt the 5-HT1A-
GalR1 heteromer through its specific interaction with 5-HT1A and therefore could 
favor a healthy phenotype [14]. These data could help explain the benefits of zinc 
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supplementation (used in depression treatment) that have been widely recognized [16, 
17]. Thus, the main scheme of this working hypothesis is based on the complex 
interplay among the GPCR-zinc-depression triad. It is plausible that the three 
aforementioned receptors, GPR39, 5-HT1A and GalR1, can be interlinked and play a 
complementary role in the molecular mechanism of depression. This is supported by 
the concept that GPCRs can form homo and heteroreceptor complexes, which may act 
as new signaling units [18-20]. 5-HT1A forms heteroreceptor complexes with different 
GPCRs [15, 21]. Therefore, the hypothesis appears valid that 5-HT1A, GPR39 and 
GalR1 can arrange into different oligomerization states where 5-HT1A is the hub 
receptor. 
We have experimentally tested the existence of the proposed interactions in order to 
gain new insights into this question. First, we have analyzed the potential 5-HT1A-
GPR39 interactions, because 5-HT1A-GalR1 heteromers had been already described 
[14, 15]. We have validated that there is co-localization between the two receptors by 
means of fluorescence microscopy. By using a complementary approach combining 
FRET (Förster resonance energy transfer) and co-immunopurification, we validate the 
interaction of 5-HT1A with GPR39 and GalR1 together or separately. Finally, we have 
used a gene reporter assay to unravel the possible signaling differences between 
mono-homomeric receptors and heteroreceptor complexes in their corresponding 
signal transduction pathways. We have analyzed 5-HT1A-GPR39 and 5-HT1A-GPR39-
GalR1 heteroreceptor complexes activities by measuring its capacity to induce the 
                                                        
1Abbreviations: 5-HT1A, 5-Hydroxytryptamine 1A receptor; 8-OH-DPAT, 7-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-
ol; DM, dodecyl maltoside; ECFP, enhanced cyan fluorescent protein; EYFP, enhanced yellow fluorescent protein; FBS, fetal 
bovine serum; FRET, Förster resonance energy transfer; gal (1-29), full length galanin peptide; GalR1, galanin receptor 1; GPCR, 
G protein-coupled receptor; hrGFP2, humanized green fluorescent protein 2; NF-RE, nuclear factor  response element; PBS, 
phosphate buffer saline; PEI, polyethylenimine; RT, room temperature; SRE, serum response element; TBS, tris buffer saline.  
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transduction over the serum response element (SRE) and nuclear factor  response 
element (NF-RE). Our results show that GPR39-5-HT1A heterocomplex has 
additive functionalities when compared to the monomeric-homomeric receptors upon 
their activation. In addition, the complex including also GalR1 shows different 
behaviour upon exposure to the same agonists. These results could reflect that both 
oligomerization forms could be present at the cell membrane and that the presence of 
one or another would depend on a specific regulation mechanism that may be 
modulated by zinc. 
 
2 Materials and methods 
2.1 Plasmid Constructs. Rho-1D4 tag is an amino acid sequence corresponding to an 
epitope located in the C-terminal tail of the bovine visual GPCR rhodopsin which is 
specifically recognized by the monoclonal Rho-1D4 antibody. This tag was added by 
inverse PCR to the expression vectors pCDNA3.1 containing either GalR1, or 5-HT1A 
or GPR39 genes (Missouri S&T cDNA Resource Center, USA). pGPR39-EYFP and 
phrGFP2-5HT1A were obtained by subcloning GPR39 into pEYFP-N3 and hrGFP2 
into pCDNA3.1-5-HT1A vectors respectively. Cloning was performed using In-
Fusion® HD Cloning Kit (Clontech, France) according to the manufacturer’s protocol. 
p5-HT1A-ECFP and pGalR1-EYFP constructs were obtained as described previously 
[15]. The pECFP-EYFP construct was obtained by subcloning PCR-amplified EYFP 
into the pECFP empty vector using traditional cloning. The used primers are listed 
below: 
pCDNA3.1-GalR1-1D4: 
Fw: 5’ACGGAGACGAGCCAGGTGGCCCCGGCCTGACTCGAGTCTAGAGGGCC 3’ 
Rv: 5’GGCCGGGGCCACCTGGCTCGTCTCCGTCACATGAGTACAATTGGTTG 3’ 
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pCDNA3.1-5-HT1A-1D4: 
Fw: 5’ACGGAGACGAGCCAGGTGGCCCCGGCCTGACTCGATAGAGGGCCCG 3’ 
Rv: 5’ GGCCGGGGCCACCTGGCTCGTCTCCGTCTGGCGGCAGAACTTACACT 3’ 
phrGFP2-5HT1A 
Fw: 5’ ACCGAGCTCGGATCCATGGTGAGCAAGCAGATCCTG 3’ 
 
Rv: 5’ ATCCATGGTGGATCCCACCCACTCGTGCAGGCTGCC 3’  
 
pGPR39-EYFP 
Fw: 5’ CTCGAGCTCAAGCTTATGGCTTCACCCAGCCTCCC 3’ 
Rv: 5’ GCGACCGGTGGATCCGCAACTTCATGCTCCTGAAAACC 3’ 
The resulting constructs were sequenced to check both appropriate cloning and 
unspecific mutation absence (Stabvida, Portugal).  
2.2 Immunofluorescence Microscopy. HEK-293S GnTi
-
 cells (EACC, UK) were 
seeded onto glass coverslips for 24 h and transfected with pGPR39-EYFP together 
with p5HT1A-1D4 using polyethylenimine (PEI) (Polysciences, Germany). 24 h after 
transfection, cells were washed with phophate buffer saline (PBS) (Sigma-Aldrich,  
Spain) and fixed with formalin 3.7% (Sigma-Aldrich, Spain) for 20 min. After 
washing twice with PBS, cells were permeabilized and blocked with blocking buffer 
(5% skimmed milk in Tris buffer saline (TBS) during 1 h at room temperature (RT). 
Then, cells were incubated first with the primary antibody, Rho-1D4 (dilution 1/2000 
from stock) for 30 min at RT. Then, after three washes with TBS buffer containing 
0.1% tween-20 (Sigma-Aldrich, Spain), the samples were incubated with anti-EYFP 
(dilution 1/200 from stock) (MBL, USA) overnight. Subsequently, secondary 
antibody incubation was performed for 1h with anti-mouse-FITC (Sigma-Aldrich, 
Spain), three washing steps as described before and 1 h more with anti-rabbit-Alexa 
Fluor® 555 (Life technologies, USA). Finally, coverslips were mounted using 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 7 
Vectashield mounting medium with DAPI (Vector Labs, UK). Representative cell 
images were taken by inverted fluorescence microscopy using Nikon Eclipse Ti 
microscope (Isaza, Spain) with a 100 x objective. 
2.3 Co-immunopurification. The constructs encoding 5-HT1A-1D4 and GPR39-EYFP 
were transiently transfected into HEK-293S GnTi
-
 cells using EI for heterodimer 
presence analysis, and the same pair together with GalR1 for trimer analysis. 
Equivalent quantities of each construct were used in both transfections. The HEK-
293S GnTi
-
 cell line was used because it provides homogeneous glycosylation and 
allows a better visualization of the protein bands in electrophoretic gels. Cells were 
routinely grown in DMEM-F12 media (Labclinics, Spain) supplemented with 10% 
fetal bovine serum (FBS), 1% penicillin-streptomycin (10000 u/ml) and 1% L-
glutamine (200 mM) (Sigma-Aldrich, Spain) at 37 ºC and 5% CO2 atmosphere. 48 h 
after transfection, cells were treated with 10 mM dimethyl apimidate (Sigma-Aldrich, 
Spain), pH 8-9, in non-supplemented DMEM-F12 media for 1 h at RT. Then cells 
were harvested and pelleted at 4000 g during 20 min. The pellet was then solubilized 
in 10 ml per harvested plate of MES buffer containing 2% Triton X-100 and 100 M 
of phenylmethylsulfonyl fluoride at 4ºC during 1 h. Solubilized cells were centrifuged, 
at 35000 rpm, for 35 min at 4ºC and the supernatant was incubated by gently nutating 
with CNBr-activated Sepharose 4B Fast Flow (GE healthcare, Spain) coupled to the 
Rho-1D4 antibody (Cell Essentials, US) during 2.5 h. The sepharose beads were 
recovered and washed with 50 mM MES buffer, pH 6.0 (Sigma-Aldrich, Spain) 
containing 0.05% dodecyl maltoside (DM) (Anatrace, UK) for five times. Elution was 
performed during 3 h with 50 mM MES buffer pH 6.0 containing 0.05% DM and 0.5 
mM Rho-1D4 9-mer peptide (TETSQVAPA) (Unitat de Tècniques Separatives i 
Síntesi de Pèptids, Universitat de Barcelona, Spain).  
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2.4 Immunoblot analysis of heterocomplexes. Eluted samples were mixed with 
denaturing loading buffer and subjected to SDS-PAGE (3-14%).  The gel was run for 
40 min at 250 V in Laemmli running buffer and using SDS7B2 pre-stained marker 
(Sigma-Aldrich, Spain) as a protein standard. The proteins were subsequently 
transferred onto a nitrocellulose membrane (Sigma-Aldrich, Spain) and blocked with 
blocking buffer. The membrane was incubated with the following pairs of antibodies, 
in three rounds separated by antibody stripping using Restore Western Blot Stripping 
Buffer (Thermo Scientific, France). The first immunoblot was performed using anti-
EYFP antibody as primary antibody (1:100 dilution from stock) and anti-rabbit-IgG-
HRP as secondary antibody (1:5000 dilution from stock). The second one was 
performed using anti-GalR1 as primary antibody (1:100 dilution from stock) and anti-
goat-IgG HRP (1:5000 dilution from stock) as secondary antibody. The third 
immunoblot was performed using Rho-1D4 (1:1000 dilution from stock) as primary 
antibody and anti-mouse-IgG-HRP as secondary antibody. All secondary antibodies 
and anti-GalR1 were purchased from Santa Cruz Biotechnology, USA. Blots were 
developed using substrate WesternBright ECL (Advansta, USA). 
2.5 FRET experiments 
2.5.1 5-HT1A-GPR39 complex detection. HEK-293S GnTi
- 
cells were transiently co-
transfected with constructs corresponding to hrGFP2-5-HT1A acting as donor and 
GPR39-EYFP acting as acceptor. hrGFP2-5-HT1A DNA amount was kept constant at 
1 g in all transfections whereas GPR39-EYFP was gradually increased as follows: 0 
g, 0.5 g, 1 g, 1.5 g, 2 g, 3 g and 4 g. 48 h after transfection, cells were 
harvested and resuspended in PBS containing 0.1 g·l
-1
 CaCl2, 0.1 g·l
-1
 MgCl2 and 0.1 
g·l
-1
 D-glucose (Sigma-Aldrich, Spain). Then, cells were seeded onto 96-well black 
plates. Cell concentration was adjusted, by determining protein concentration with a 
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BCA kit (Sigma-Aldrich, Spain), to 1 mg/ml. Finally, FRET signals were measured 
using an Infinite M200 reader (Tecan, Switzerland). Fluorescence was measured at 
three different conditions: 1- Ex = 485 nm and Em = 516 nm, for hrGFP2 signal 
detection; 2-Ex = 515 nm and Em = 546 nm for EYFP signal detection; 3- Ex = 
485nm and Em = 546 nm for FRET signal detection. Mock transfected cells were 
used for background subtraction. FRET between the two fluorophores was determined 
essentially as previously described [22]. 
2.5.2 GalR1 -5-HT1A-GPR39 complex detection. To carry out this experiment we 
used the following vectors: p5HT1A-ECFP as donor, pGalR1-EYFP as acceptor and 
pECFP-EYFP as a negative control. Cells were transfected in six well plates using the 
following conditions: donor alone, donor and acceptor (1:1 ratio) and negative control. 
Same transfections were repeated as described but also adding pCDNA3.1-GPR39 at 
equivalent concentrations. FRET spectra were recorded using an Infinite M200  
reader. Excitation wavelength was set at 420 nm and emission wavelength range was 
set from 455 nm to 560 nm. Data was smoothed and normalized using Peakfit 
software (Systat Software, USA). 
2.6 Luciferase reporter gene assay. We used Bright-Glo™ Luciferase Assay System 
(Promega, Spain) to detect receptor activation. Reporter gene vectors containing 
luciferase transcriptionally driven by response elements (pGL4.33 and pGL4.32) were 
used in these experiments. Cells were co-transfected, in each case, with the 
corresponding reporter vector and receptors, at equivalent DNA amounts, using 6 well 
plates. 24 h after transfection, cells were transferred onto 96 well white plates (Perkin 
Elmer, USA) in starving media (culture media without FBS). Cells were subsequently 
treated during 4 h, after additional 24 h, with the appropriate ligand concentration in 
Optimem (Life Technologies, USA). 8-OH-DPAT at a concentration of 100 M was 
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used as 5-HT1A agonist, 100 M ZnCl2 as GPR39 agonist and 1 M gal (1-29) as 
GalR1 agonist. Luciferase activity was determined according to the manufacturer’s 
protocol with an Infinity M200 reader, using standard luminescence reading 
conditions. Experiments were performed in triplicate, and four replicates were 
measured in each experiment. Statistical analyses were performed by one tailed paired 
t-test with GraphPad Prism (GraphPad Software Inc, USA). A p value of 0.05 and 
lower was considered significant. 
 
3 Results 
3.1 Immunofluorescence microscopy. One of the main objectives of this work was to 
determine the potential formation of a 5-HT1A and GPR39 heteroreceptor complexes 
in cellular model by means of FRET and co-immunopurification assays. To start with, 
first we determined if the C-terminal tagged 5-HT1A-1D4 and GPR39-EYFP receptors 
co-localized to the same cell compartment. Double immunolabeling of the tagged 5-
HT1A-1D4 receptor with anti-1D4/FITC and the tagged GPR39-EYFP with the anti-
EYFP/Alexa-Fluor555 antibodies showed that both receptors share a similar 
distributional pattern and significantly co-localized in the membrane cell surface and 
reticular compartments (Figure 1A-F).   
3.2 Heterodimerization between 5-HT1A and GPR39 measured by FRET 
We tested the possible heteromer formation between both receptors by means of the 
biophysical technique FRET spectroscopy. Using a saturation assay we assessed 
specific FRET between the two receptors, in cells co-expressing a constant amount of 
hrGFP2-5-HT1A (humanized green fluorescent protein 2 fused to the C-terminal tail of 
the 5-HT1A) (donor) and an increasing concentration of GPR39-EYFP (GPR39 
receptor fused to enhanced yellow fluorescent protein) (acceptor). For unspecific 
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FRET measurements, two populations of cells were independently transfected with a 
single construct and subsequently mixed. Our data can be fit to a hyperbolic curve 
with an asymptote tending to the maximal FRET value (Figure 1G), validating the 
specific interaction between the two receptors. In contrast, unspecific FRET 
measurements resulted in a linear relationship between n-FRET and acceptor-to-donor 
ratios reflecting lack of interaction between the two mixed populations of cells 
expressing the individual receptors. Taken together, these results demonstrate that 
there is specific complex formed between GPR39 and 5-HT1A.  
3.3 5-HT1A and GPR39 heteromer analysis using co-immunopurification 
We used co-immunopurification in order to provide further support to our FRET 
measurements on purified receptors. Heterocomplex formation among the three 
receptors (including GalR1) was also tested using the same methodology (Figure 2A). 
For heterodimerization experiments cells were co-transfected with equivalent amounts 
of 5-HT1A-1D4 and GPR39-EYFP. The same amount of GalR1 was added for 
heterotrimerization experiments. Immunopurification was carried out by 
immunoaffinity chromatography using the Rho-1D4 monoclonal antibody. GalR1-
1D4 and 5-HT1A-1D4 were singly transfected, obtained separately and 
immunopurified to be used as immunoblot controls. Immunoblot analysis showed 
EYFP immunoreactive bands both in heterodimer and heterotrimer lanes, but with a 
different migration pattern. Both lanes showed two high molecular mass species as 
upper bands, but in the case of the dimer two lower bands could be detected and only 
one in the case of the trimer. No immunoreactive bands could be detected in control 
lanes as expected. When the inmunoblot was carried out using the anti-GalR1 
antibody, immunoreactive bands appeared in the GalR1 control lane and in the trimer 
lane. Finally when the immunoblot was performed using Rho-1D4 antibody, we could 
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detect signal in all lanes indicating that the immunopurification process worked 
successfully (Figure 2A). These results indicated that we had purified the 5-HT1A-
GPR39 heteromer and the GPR39-5-HT1A-GalR1 complex. It can be noted that we 
could detect monomeric species for 5-HT1A and GalR1 corresponding to the bands in 
the control lanes, but no further information could be derived from the other bands in 
our denaturing conditions.  It is also noteworthy to indicate that in the trimer lane, the 
band intensity obtained for GalR1 was lower than the intensity seen for the bands 
corresponding to the other two proteins. In other to discard the possible predominance 
of 5-HT1A-GPR39, when compared to 5-HT1A-GPR39-GalR1, we analyzed the FRET 
curves between 5-HT1A-ECFP and GalR1-EYFP in the presence and in the absence of 
GPR39 at equivalent amounts.  
3.4 Heterotrimer confirmation by FRET 
In order to confirm the existence of a putative complex formed by our three working 
receptors, we measured FRE  curves between 5-HT1A and GalR1 receptors in the 
presence and in the absence of GPR39 and we compared them with those obtained 
using a negative control, also in presence and absence of the same receptor (Figure 
2B). FRET was apparent in both samples and it had exactly the same shape. Two 
peaks could be clearly distinguished, one at 490 nm corresponding to ECFP 
(enhanced cyan fluorescent protein) and the other at 527 nm corresponding to EYFP, 
indicating that FRET was actually taking place. Thus, 5-HT1A maintained its capacity 
to interact with GalR1 in the presence of GPR39. The same result was obtained for the 
negative control as expected (Figure 2C).  
3.5 SRE and NF-RE luciferase reporter assays  
Luciferase reporter assays were carried out with the purpose of analyzing differences 
in receptors signaling due to heteromer formation. Briefly, these assays are based on 
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the fact that different GPCRs are able to activate different regulatory elements via 
interaction with specific G proteins populations. Therefore, activation of the different 
response elements can be an indirect measurement of receptor activation. In this 
particular case we measured SRE and NF-RE activation. These two pathways were 
chosen because of the following reasons: on the one side, GPR39 signals via Gq, 
G12/13 and Gs after stimulation with zinc, and the activation of these G proteins 
leads to different pathways that have as endpoints the activation of both response 
elements mentioned above, among others [12, 23]. On the other side, 5-HT1A couples 
exclusively to Gi/G0 that just activates SRE when 8-OH-DPAT is used as agonist [15]. 
This different behavior in receptor signaling is used to derive information about 
specific signaling of our studied receptors. The ability of our receptors to signal as 
mentioned and according to previously published data was experimentally tested (data 
not shown). 
Heteromer exposure to 8-OH-DPAT or ZnCl2 resulted in a significant SRE response 
compared to non-exposed samples (p<0.05) (Figure 3A) meaning that in the complex 
formed both receptors are active. Also, exposure to both compounds at the same time 
gave a significantly higher response compared to those exhibited by each one of the 
compounds on its own. These findings provide experimental evidence for additive 
signaling upon co-activation. But, if we take into account that the presence of zinc 
decreases 5-HT1A signaling ability, as it has been published [24] and we have 
experimentally tested (see Figure S1), a plausible interpretation is that co-activation of 
both receptors increases GPR39 activity. In contrast, no activity could be detected 
after 8-OH-DPAT exposure alone (Figure 3B) when analyzing NF-RE signaling. 
This result is in agreement with the fact that 5-HT1A is not able to signal via NF-RE 
and 8-OH-DPAT is not able to activate the GPR39 receptor. However, ZnCl2 
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provided a significant signal increase because of GPR39 activation. Furthermore, 
upon co-activation of the two receptors the signal was significantly increased when 
compared to the signal corresponding to ZnCl2 exposure alone. These results could 
mean that in the oligomeric state, and after co-activation of the two receptors, 
activation of 5-HT1A enhances GPR39 activity, as it is also suggested by SRE results, 
or alternatively changes 5-HT1A signaling possibilities. 
Strikingly, the presence of GalR1 blocks 5-HT1A and GPR39 signaling (Figure 4). 
Thus, no SRE activation could be detected, in the presence of GalR1, when cells were 
incubated with 8-OH-DPAT or ZnCl2, whereas a significantly enhanced response 
could be observed when the sample was treated with gal (1-29) peptide (galanin full 
length peptide). Moreover, stimulation with all agonists together yielded the same 
response as gal (1-29) alone. We conclude that when the three receptors interact, only 
GalR1 is able to transduce signals trough the analyzed pathway. 
 
4 Discussion 
The relationship between 5-HT1A-GalR1 heteromer, depression and zinc has been 
previously postulated [14]. The potential linkage of GPR39 with zinc and its role in 
depression has also been proposed [4, 17, 25]. Also, a link between zinc and serotonin 
has been described, suggesting that serotonin levels can modulate GPR39 expression 
[26]. However, in spite of these potential associations, no experimental results have 
been reported on a direct relationship among the four studied elements (5-HT1A-GalR1, 
GPR39, zinc and depression). Our first characterization validated the co-localization 
of 5-HT1A and GPR39 in co-transfected cells and this work was continued by testing 
for heteromerization. In fact, heteromerization was demonstrated between the two 
receptors by means of FRET spectroscopy. 5-HT1A was found to interact with both 
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GalR1 and GPR39 suggesting a possible heteroreceptor complex formed by these 
three receptors. Such heterotrimer receptor complexes have previously been described 
for different GPCRs belonging to the same family [27, 28].  
The hypothesis was tested by using co-immunopurification. This method also allowed 
validating our previous FRET results indicating the existence of a 5-HT1A-GPR39 
heteromer.  Immunoblots sustained the hypothesis of a heterotrimer built up of these 
three receptors. In the lane where the putative GalR1-5-HT1A-GPR39 complex had 
been loaded, signals were obtained when using the antibodies against each of the three 
proteins. However, in the lane where putative 5-HT1A-GPR39 heteromers had been 
loaded, the signal was missing when using the anti-GalR1 antibody. Also control lanes 
showed signals according to the antibody used. Furthermore, the signal corresponding 
to GalR1 in the trimer lane was weaker compared to controls and signals 
corresponding to the other two proteins (Figure 2A). As transfection had been done 
with equivalent concentrations of each cDNA, two explanations may be given for this 
result. On one side we can have the predominance of the 5-HT1A-GPR39 heteromer 
versus the heterotrimer, and on the other side the possibility of an artifact, due to the 
high level of purified sample processed, cannot be ruled out. Alternatively, it is also 
possible that different receptor expression levels could be responsible for the different 
band intensities observed.  FRET curves were recorded between 5-HT1A and GalR1 in 
the presence or in the absence of GPR39. The presence of GPR39 did not modify 
FRET between the other two receptors, ruling out the possible predominance of 5-
HT1A-GPR39 heterodimer. If 5-HT1A-GPR39 had prevailed over the GalR1-5-HT1A-
GPR39 trimer, FRET may not have been observed. Two mechanisms can account for 
this behavior: the three receptors together form a stable complex or the predominance 
of one over the two different possible oligomers depends on cell type or specific 
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physiological states.  
The paradigm accepted for GPCRs oligomerization is that these receptors, as 
protomers, use this strategy in order to exponentially multiply their signaling 
capabilities [18]. Therefore, the main signaling characteristics of the heterodimer and 
the heterotrimer were further investigated. 
 Different signaling patterns were obtained for the heterodimer and the heterotrimer 
that were also different from the signaling pattern already published for the 5-HT1A 
and GalR1 heteromer. The 5-HT1A-GalR1 heteromer shows trans-inhibition. Thus, 
when both receptors are ligand activated, the activity is exactly the same as that 
obtained when only one of the receptors is activated, either GalR1 or 5-HT1A [15]. 
However, in the case of the GPR39-5-HT1A-GalR1 heterotrimer, GalR1 acts as an 
antagonist blocking SRE signaling of the other two receptor protomers regardless of 
the fact that it is agonist activated or not. 5-HT1A-GPR39 meanwhile shows additive 
increase in signaling along the SRE and NF-RE pathways when both receptor 
protomers are agonist activated. This result is not consistent with monomer-homomer 
activity if we take into account that 5-HT1A is not able to signal via NF-RE. These 
findings suggest that heterodimerization confers new signaling opportunities to 5-
HT1A and GPR39. 
Our previous results strongly suggested that zinc disrupts the 5-HT1A-GalR1 
heteromer [29]. Moreover, it was described that GPR39 knock-out mice exhibit 
depression-like behavior [25] and that zinc deficiency strongly decreased GPR39 
expression, and gave depression-like behavior in rodents [12, 13]. As a conclusion, 
the following scenario is introduced: zinc concentration regulates the oligomerization 
state between the three receptors GalR1-5-HT1A-GPR39 and this may have 
consequences in the regulation of the depressive behavior. At high zinc levels, 5-HT1A 
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would no longer be able to interact with GalR1, but could do so with GPR39, which is 
expressed at appropriate levels. In contrast, at zinc deficient levels, the predominant 
form would be 5-HT1A-GalR1 (vs 5-HT1A-GPR39) since this heteroreceptor complex 
is not disrupted, and GPR39 levels might be low. The heterotrimer complex formed 
from the three receptors could be an intermediate between the two heterodimer 
complex states (Figure 5). It is really difficult to associate a defined zinc 
concentration to each of the aforementioned states because the zinc concentration in a 
specific cell environment has not been clearly established. It depends on the cell type, 
and also on the specific state of the cell, varying from nM to mM concentrations [24]. 
However, according to previous reports [14, 24] 50M should be considered a zinc 
concentration high enough to prevent depression. 
Future work must strive to unravel the exact regulatory mechanism that zinc exerts on 
the oligomerization states among these distinct receptors (5-HT1A-GPR39, 5-HT1A-
GalR1 and GalR1-5-HT1A- GPR39) followed by validation of our results using human 
samples, and suitable techniques like PLA (proximity ligation assay). A full 
understanding of this process will increase the possibilities in the field of drug 
discovery and design in order to develop novel antidepressant drugs, involving e.g. 
specific divalent ligands for the heteroreceptor targets. 
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7 Figures 
 
 
 
Figure 1. 5-HT1A-GPR39 heterodimerization. (A-F) Co-localization of 5-HT1A and 
GPR39 expressed in HEK293S GnTi
-
 cells. 5-HT1A corresponds to the green signal 
(A and D) and GPR39 to red signal (B and E). Green and red signal overlap is shown 
by the yellowish color giving the area of receptor co-localization (C and F). Pictures 
show the area of colocalization (white arrows) of the two receptors, which in F is 
clearly demonstrated along the cell membrane and endoplasmic reticulum. (G) FRET 
saturation curve between 5-HT1A and GPR39. N-FRET (normalized FRET values) are 
represented against the acceptor to donor ratio. Specific FRET, corresponding to the 
co-transfection of hrGFP2-5-HT1A and GPR39-EYFP, () is indicated from the 
saturation profile of the curve. In contrast, unspecific FRET ( ) measurements, 
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corresponding to mixed populations of cells expressing single receptors, exhibit a 
linear tendency corresponding to a non-specific interaction. Data corresponds to the 
average of three independent experiments. Data reflect specific interactions between 
the two receptors. 
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Figure 2. Specific heterooligomer formation between 5-HT1A-GPR39 and 5-
HT1A-GPR39-GalR1. (A) Co-immunopurification immunoblots.  Heterocomplexes 
were immunopurified by adding the 1D4 tag to 5-HT1A in combination with Rho-1D4 
antibody coupled sepharose. Four lanes were loaded with the following samples: 5-
HT1A-1D4 (a), GalR1-1D4 (b), 5-HT1A-1D4 + GPR39-EYFP (c) and 5-HT1A-1D4 + 
GPR39-EYFP + GalR1 (d). Interaction between 5-HT1A-1D4 and GPR39-EYFP is 
detected. Moreover, interaction between 5-HT1A-1D4, GPR39-EYFP and GalR1 are 
also detected. 5-HT1A-1D4 and GalR1-1D4 were used as control lanes. (B-C) FRET 
curves between 5-HT1A-ECFP and GalR1-EYFP. (B) Curves were obtained by 
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cotransfection using two different conditions: 5-HT1A-ECFP + GalR1-EYFP (   ) and 
5-HT1A-ECFP + GalR1-EYFP + GPR39 (---) at equivalent concentrations. 5-HT1A-
ECFP + GalR1-EYFP + GPR39 (---) data are nudged 0.1 points to avoid overlap. No 
differences between both curves are seen, meaning that 5-HT1A-GPR39 is not the 
predominant form. (C) The same experiment was carried out using ECFP-EYFP 
fusion protein as a negative control (positive control in FRET determination 
experiments).  
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Figure 3. SRE and NF-RE luciferase reporter gene assay of signaling over the 
5-HT1A-GPR39 heteroreceptor complex. Mock transfected cells correspond to cells 
transfected without DNA and non-exposed cells to cells transfected but not agonist- 
stimulated. (A) SRE assay response after stimulation of co-transfected cells with 8-
OH-DPAT, ZnCl2 or both at the same time was measured. In the three cases we 
obtain signals significantly stronger compared to that of the control (non exposed). 
Co-activation by agonists, at the same time, gives a significantly stronger signal than 
the ones obtained for single receptors demonstrating additive signaling. (B) NF-RE 
response under the same conditions as earlier. In this case, 8-OH-DPAT activation of 
the complex is not observed, because 5-HT1A cannot act through NF-RE. In 
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contrast, activation mediated by both compounds exhibits a signal significantly higher 
compared to that obtained with ZnCl2 activation alone. (A-B) The data represent the 
means ± SD of three independent experiments performed in triplicate. Statistical 
analyses were performed by one tailed paired t-test. Significantly different group 
comparisons are represented with *** (P < 0.001), ** (P ≤ 0.01) and * (P ≤ 0.05) and 
non significantly different as ns (P > 0.05). (C) Schematic representation of signaling 
pattern changes between mono-homomeric forms and dimeric forms. Signaling 
through NF-RE is reinforced due to 5-HT1A-GPR39 heteromer formation. Adapted 
from [30] and [23]. Diamonds stand for receptors specific ligands.  
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Figure 4. SRE luciferase reporter gene assay of signaling over the 5-HT1A-
GPR39-GalR1 complex. Mock transfected cells correspond to cells transfected 
without DNA and non-exposed cells to transfected but not agonist-stimulated cells. 
(A) SRE assay response was measured after stimulation of co-transfected cells with 8-
OH-DPAT, ZnCl2, gal (1-29) alone, or all combined. No response was obtained after 
stimulation with 8-OH-DPAT, or ZnCl2, whereas a response could be detected after 
GalR1 stimulation. Moreover, combined agonist activation of all receptors at the same 
time gives the same response as GalR1 stimulation alone. The results indicate that the 
GalR1 presence blocks SRE signaling of 5-HT1A and GPR39 protomers in GalR1-5-
HT1A-GPR39 heteroreceptor complex. (A-B) The data represent the means ± SD of 
three independent experiments performed in triplicate. Statistical analyses were 
performed by one tailed paired t-test. Significantly different group comparisons are 
represented with *** (P < 0.001), ** (P ≤ 0.01) and * (P ≤ 0.05) and non significantly 
different as ns (P > 0.05).  (B) Schematic representation of the ERK 1/2-SRE 
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signaling mechanism, found only in the GalR1 protomer while this signaling pathway 
is blocked in the 5-HT1A and GPR39 protomers of this heteroreceptor complex. Other 
unknown pathways may be in operation at these protomers, adapted from [30] and 
[23]. Diamonds stand for receptors specific ligands. 
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Figure 5.  Putative mechanism for zinc regulation of the balance of 
heteroreceptor complexes in which 5-HT1A protomers participate with GPR39 
and/or GalR1 protomers. High zinc concentrations counteract 5-HT1A-GalR1 
heteromer formation which is replaced by the formation of 5-HT1A-GPR39 
heteromers. Instead, when zinc concentrations decrease, the 5-HT1A-GalR1 heteromer 
develops as the dominant form due to the decrease in GPR39 expression. In this 
process, the 5-HT1A-GPR39-GalR1 heteroreceptor complex participates as an 
intermediate form between the two heterodimers. 
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Graphical Abstract 
Highlights 
 
 
· GPR39 is able to form heterodimers with 5-HT1A upon co-expression of the two 
receptors in mammalian cells. 
 
· GPR39, 5-HT1A and GalR1 are able to form heterotrimers upon co-expression of the 
three receptors in mammalian cells. 
 
· GPR39, 5-HT1A and GalR1 exhibit different signaling properties when they are 
engaged in heterocomplexes compared to their monomeric states. Signaling properties 
of the same receptors are different depending on the heterocomplex they belong to. 
 
· The balance among the three different forms, 5-HT1A -GalR1, GPR39-5-HT1A -GalR1 
and GPR39-5-HT1A would be regulated by zinc and may be one of the potential 
mechanisms  involved in the physiopathology of depression. 
